Azalea Therapeutics

Biotechnology · Berkeley, CA · Founded 2023 · Privately Held (backing)

Operator of a biotechnology platform intended to enable precise genome editing inside the body for disease treatment. Azalea Therapeutics is based in Berkeley, CA and was founded in 2023. It was valued at $153 million at its early-stage round in Oct 2025, the last priced event on record. It has raised $82 million across 1 recorded round; the latest was a $65 million Series A in Oct 2025.

PMV mark · valuation
$153.0M
Oct 2026
Priced at
its early-stage round
Oct 2025
Total raised
$82.0M
Last round
Early Stage VC (Series A)
Oct 2025
What is Azalea Therapeutics worth?
$153.0MPrivateMarketView mark · Oct 2026

Valued at $153.0M at its early-stage round, Oct 2025. Nothing has traded since.

Free account
More of Azalea Therapeutics with a free account
  • ·Watch Azalea Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Azalea Therapeutics funding history

1 rounds
DateRoundRaisedPost-money
Oct 2025Early Stage VC (Series A)$65.0M▮
Unlock post-money valuations

Membership and data by Private Market View

Azalea Therapeutics valuation

Azalea Therapeutics was valued at $153 million at its early-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Azalea Therapeutics raised?

Azalea Therapeutics has raised $82 million in total; 1 of its rounds is on record. The largest on record was a $65 million Series A in Oct 2025.

Comparable companies

Comparable biotechnology names by valuation on PrivateMarketView: Ambros Therapeutics ($250 million), Gameto ($243 million) and Antheia ($240 million).

How Azalea Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Azalea Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Azalea Therapeutics

What is Azalea Therapeutics worth?
Azalea Therapeutics is valued at $153.0M as of Oct 2026. Valued at $153.0M at its early-stage round, Oct 2025. Nothing has traded since.
How much has Azalea Therapeutics raised?
Azalea Therapeutics has raised $82.0M in total funding across 1 recorded rounds.
When did Azalea Therapeutics last raise?
Azalea Therapeutics last raised in Oct 2025 (Early Stage VC (Series A)), raising $65.0M.